INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251301, 'Dalfopristin', 'Rimegepant', 'Moderate', 'Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of rimegepant, which is primarily metabolized by the isoenzyme.', 'DDInter', 'Following concomitant administration with a moderate CYP450 3A4 inhibitor, the manufacturer recommends avoiding another dose of rimegepant within 48 hours.', 'Metabolism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297644/', '', 'Frovatriptan, Eptinezumab, Lasmiditan, Rizatriptan, Naratriptan, Galcanezumab, Zolmitriptan, Sumatriptan, Erenumab, Clonidine, Almotriptan, Fremanezumab', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251302, 'Dalfopristin', 'Ripretinib', 'Moderate', 'Coadministration of moderate or weak CYP450 3A4 inhibitors with ripretinib may increase the plasma concentrations and the risk of adverse effects (e.g., palmar-plantar erythrodysesthesia, hypertension, cardiac dysfunction, arthralgia/myalgia) of ripretinib and its active metabolite (DP-5439).  The proposed mechanism is inhibition of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of ripretinib and DP-5439.', 'DDInter', 'Caution is recommended when ripretinib is used concomitantly with a moderate or weak CYP450 3A4 inhibitor.  Clinical and laboratory monitoring should be considered whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy with ripretinib, and the dosage adjusted as necessary.  Patients should be monitored for development of adverse effects.', 'Metabolism', 'Caution is recommended when ripretinib is used concomitantly with a moderate or weak CYP450 3A4 inhibitor.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297645/', '', 'Dabrafenib, Dacomitinib, Vemurafenib, Vandetanib, Afatinib, Tivozanib, Sunitinib, Regorafenib, Alpelisib, Lenvatinib, Erlotinib, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251303, 'Dalfopristin', 'Ritonavir', 'Moderate', 'Based on in vitro inhibition data, coadministration with dalfopristin-quinupristin may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme.  The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by dalfopristin-quinupristin.', 'DDInter', 'Caution is advised if dalfopristin-quinupristin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dalfopristin-quinupristin is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if dalfopristin-quinupristin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297646/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251304, 'Dalfopristin', 'Rivaroxaban', 'Moderate', 'Coadministration with moderate or potent inhibitors of CYP450 3A4 may increase the plasma concentrations of rivaroxaban, which is a substrate of the isoenzyme.', 'DDInter', 'In patients with significant renal impairment (e.g., CrCl between 15 to 50 mL/min), the use of rivaroxaban with moderate or potent inhibitors of CYP450 3A4 should be approached with caution.  Patients should be routinely evaluated for signs and symptoms suggesting blood loss such as a drop in hemoglobin and/or hematocrit, hypotension, or fetal distress (in pregnant women).  Renal function should also be assessed periodically, and treatment with rivaroxaban discontinued if acute renal failure develops.  Due to the lack of clinical data, rivaroxaban is not recommended in patients with CrCl below 30 mL/min when used for the prophylaxis of deep vein thrombosis and in patients with CrCl below 15 mL/min when used for reducing the risk of stroke and systemic embolism in nonvalvular atrial fibrillation.', 'Metabolism', 'In patients with significant renal impairment (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297647/', '', 'Betrixaban, Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Warfarin, Caplacizumab, Argatroban, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251305, 'Dalfopristin', 'Ropivacaine', 'Minor', 'Coadministration with inhibitors of CYP450 3A4 may modestly increase the plasma concentrations of ropivacaine.  Although ropivacaine is primarily metabolized by CYP450 1A2, it has been shown to undergo some metabolism via CYP450 3A4.', 'DDInter', 'CYP450 3A4 inhibitors have a significant effect on the pharmacokinetics of ropivacaine only in the presence of CYP450 1A2 inhibitors such as fluvoxamine, ciprofloxacin, or mexiletine. Therefore, the combination of ropivacaine and the above drugs is not recommended.', 'Metabolism', 'CYP450 3A4 inhibitors have a significant effect on the pharmacokinetics of ropivacaine only in the presence of CYP450 1A2 inhibitors such as fluvoxamine, ciprofloxacin, or mexiletine.', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297649/', '', 'Chloroprocaine, Bupivacaine, Tetracaine, Mepivacaine, Meloxicam, Procaine, Prilocaine, Articaine, Etidocaine', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251306, 'Dalfopristin', 'Rucaparib', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations and the risk of adverse effects of rucaparib, which has been shown in vitro to be a substrate of the isoenzyme.', 'DDInter', 'Caution is advised if rucaparib is used concomitantly with potent CYP450 3A4 inhibitors.  Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever a potent CYP450 3A4 inhibitor is added to or withdrawn from therapy with rucaparib.', 'Metabolism', 'Caution is advised if rucaparib is used concomitantly with potent CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297650/', '', 'Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251307, 'Dalfopristin', 'Ruxolitinib', 'Minor', 'Coadministration with mild or moderate inhibitors of CYP450 3A4 may modestly increase the plasma concentrations of ruxolitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 'Coadministration with mild or moderate inhibitors of CYP450 3A4 may modestly increase the plasma concentrations of ruxolitinib, which is primarily metabolized by the isoenzyme.  In healthy subjects, administration of a single 10 mg dose of ruxolitinib following pretreatment with the moderate CYP450 3A4 inhibitor erythromycin (500 mg twice daily for four days) resulted in an 8% increase in ruxolitinib peak plasma concentration (Cmax) and a 27% increase in systemic exposure (AUC) compared to administration of ruxolitinib alone.  The change in the pharmacodynamic marker, pSTAT3 inhibition, was consistent with the corresponding exposure information.  No dosage adjustment is recommended when ruxolitinib is coadministered with mild or moderate CYP450 3A4 inhibitors.', 'Metabolism', 'Coadministration with mild or moderate inhibitors of CYP450 3A4 may modestly increase the plasma concentrations of ruxolitinib, which is primarily metabolized by the isoenzyme.', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297651/', '', 'Dabrafenib, Dacomitinib, Vemurafenib, Vandetanib, Afatinib, Tivozanib, Sunitinib, Regorafenib, Alpelisib, Lenvatinib, Erlotinib, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251308, 'Dalfopristin', 'Saquinavir', 'Moderate', 'Based on in vitro inhibition data, coadministration with dalfopristin-quinupristin may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme.  The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by dalfopristin-quinupristin.', 'DDInter', 'Caution is advised if dalfopristin-quinupristin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dalfopristin-quinupristin is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if dalfopristin-quinupristin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297652/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251309, 'Dalfopristin', 'Saxagliptin', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may alter the plasma concentrations of saxagliptin and its pharmacologically active metabolite, both of which are substrates of the isoenzyme.', 'DDInter', 'Pharmacologic response to saxagliptin should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy.  Patients should be advised to regularly monitor their blood sugar and counseled on how to recognize and treat hypoglycemia, which may include symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, and palpitations.  The physician should be notified if an interaction is suspected.', 'Metabolism', 'Pharmacologic response to saxagliptin should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297653/', '', 'Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251310, 'Dalfopristin', 'Selpercatinib', 'Major', 'Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of selpercatinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 'Concomitant use of selpercatinib with moderate CYP450 3A4 inhibitors should generally be avoided.  If coadministration is required, the manufacturer recommends decreasing the dosage of selpercatinib.  Patients receiving selpercatinib 120 mg twice daily should have the dosage reduced to 80 mg twice daily, and those receiving 160 mg twice daily should have the dosage reduced to 120 mg twice daily.  Close monitoring for adverse effects is advisable, including more frequent ECGs and laboratory monitoring of liver enzymes, bilirubin, electrolytes, glucose, and blood counts.  Selpercatinib treatment should be discontinued, interrupted, or dosage reduced in patients with serious or life-threatening toxicities in accordance with the product labeling.  After the inhibitor has been discontinued for 3 to 5 elimination half-lives, the selpercatinib dosage that was taken prior to initiating the inhibitor may be resumed.', 'Metabolism', 'Concomitant use of selpercatinib with moderate CYP450 3A4 inhibitors should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297654/', '', 'Dabrafenib, Dacomitinib, Vemurafenib, Vandetanib, Afatinib, Tivozanib, Sunitinib, Regorafenib, Alpelisib, Lenvatinib, Erlotinib, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251311, 'Dalfopristin', 'Selumetinib', 'Major', 'Coadministration with potent or moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of selumetinib, which is primarily metabolized by CYP450 3A4 and to a lesser extent by CYP450 2C19, 1A2, 2C9, 2E1, and 3A5.  Selumetinib also undergoes glucuronidation by UGT1A1 and UGT1A3.', 'DDInter', 'Concomitant use of selumetinib with potent or moderate CYP450 3A4 inhibitors should generally be avoided.  If coadministration is required, a reduction in the dosage of selumetinib is recommended.  Patients receiving selumetinib 25 mg/m2 twice daily should have the dosage reduced to 20 mg/m2 twice daily, and those receiving 20 mg/m2 twice daily should have the dosage reduced to 15 mg/m2 twice daily.  Further dosage adjustments should be made according to clinical response and tolerance.  Please refer to the product labeling for more detailed information on dosing adjustments.  After discontinuation of the strong or moderate CYP450 3A4 inhibitor for 3 elimination half-lives, the selumetinib dosage that was taken prior to initiating the inhibitor may be resumed.', 'Metabolism', 'Concomitant use of selumetinib with potent or moderate CYP450 3A4 inhibitors should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297655/', '', 'Dabrafenib, Dacomitinib, Vemurafenib, Vandetanib, Afatinib, Tivozanib, Sunitinib, Regorafenib, Alpelisib, Lenvatinib, Erlotinib, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251312, 'Dalfopristin', 'Sertraline', 'Moderate', 'Based on in vitro inhibition data, coadministration with dalfopristin-quinupristin may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme.  The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by dalfopristin-quinupristin.', 'DDInter', 'Caution is advised if dalfopristin-quinupristin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dalfopristin-quinupristin is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if dalfopristin-quinupristin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297656/', '', 'Maprotiline, Fluoxetine, St. John''s Wort, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Viloxazine, Amoxapine, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251313, 'Dalfopristin', 'Sibutramine', 'Minor', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of sibutramine and its active metabolites, which are metabolized by the isoenzyme.', 'DDInter', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of sibutramine and its active metabolites, which are metabolized by the isoenzyme.  Inhibitors such as ketoconazole, cimetidine, and erythromycin have caused moderate increases in the peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) of the active metabolites.  The data suggest that although the potential for such interaction exists, the magnitude appears to be small.  No special precaution appears necessary; however, dosage adjustments as well as clinical and laboratory monitoring may be appropriate in some cases when a CYP450 3A4 inhibitor is added to or withdrawn from therapy.', 'Metabolism', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of sibutramine and its active metabolites, which are metabolized by the isoenzyme.', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297657/', '', 'Dexfenfluramine, Naltrexone, Ephedrine, Fenfluramine, Bupropion, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251314, 'Dalfopristin', 'Sildenafil', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of sildenafil, which is primarily metabolized by the isoenzyme.', 'DDInter', 'Caution is advised if sildenafil is coadministered with CYP450 3A4 inhibitors.  Dosage adjustments may be appropriate for sildenafil whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy based on efficacy and side effects.  Patients should be advised to promptly notify their physician if they experience pain or tightness in the chest or jaw, irregular heartbeat, nausea, shortness of breath, visual disturbances, syncope, or prolonged erection (greater than 4 hours).', 'Metabolism', 'Caution is advised if sildenafil is coadministered with CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297658/', '', 'Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251315, 'Dalfopristin', 'Silodosin', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of silodosin, which is primarily metabolized by the isoenzyme.', 'DDInter', 'Caution is advised if silodosin is prescribed in combination with inhibitors of CYP450 3A4.  Pharmacologic response to silodosin should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the silodosin dosage adjusted as necessary.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  Taking silodosin at bedtime may minimize the occurrence of orthostatic effects.  Patients should also avoid driving or operating hazardous machinery until they know how the medication affects them.', 'Metabolism', 'Caution is advised if silodosin is prescribed in combination with inhibitors of CYP450 3A4.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297659/', '', 'Finasteride, Terazosin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251316, 'Dalfopristin', 'Simvastatin', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of HMG-CoA reductase inhibitors (i.e., statins) that are metabolized by the isoenzyme.  Lovastatin and simvastatin are particularly susceptible because of their low oral bioavailability, but others such as atorvastatin and cerivastatin may also be affected.  High levels of HMG-CoA reductase inhibitory activity in plasma is associated with an increased risk of musculoskeletal toxicity.  Myopathy manifested as muscle pain and/or weakness associated with grossly elevated creatine kinase exceeding ten times the upper limit of normal has been reported occasionally.  Rhabdomyolysis has also occurred rarely, which may be accompanied by acute renal failure secondary to myoglobinuria and may result in death.  Clinically significant interactions have been reported with potent CYP450 3A4 inhibitors such as macrolide antibiotics, azole antifungals, protease inhibitors and nefazodone, and moderate inhibitors such as amiodarone, cyclosporine, danazol, diltiazem and verapamil.', 'DDInter', 'Caution is recommended if atorvastatin, cerivastatin, lovastatin, simvastatin, or red yeast rice (which contains lovastatin) is prescribed with a CYP450 3A4 inhibitor.  It is advisable to monitor lipid levels and use the lowest effective statin dose.  All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  Fluvastatin, pravastatin, and rosuvastatin are not expected to interact with CYP450 3A4 inhibitors.', 'Metabolism', 'Caution is recommended if atorvastatin, cerivastatin, lovastatin, simvastatin, or red yeast rice (which contains lovastatin) is prescribed with a CYP450 3A4 inhibitor.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297660/', '', 'Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251317, 'Dalfopristin', 'Siponimod', 'Major', 'Coadministration with drugs that cause moderate inhibition of CYP450 2C9 and moderate or strong inhibition of CYP450 3A4 may increase the plasma concentrations of siponimod, which is primarily metabolized by these isoenzymes.  This interaction includes concomitant use of siponimod with a moderate CYP450 2C9/3A4 dual inhibitor or a moderate CYP450 2C9 inhibitor in combination with a separate moderate or strong CYP450 3A4 inhibitor.', 'DDInter', 'Concomitant use of siponimod with a moderate or strong CYP450 2C9/3A4 dual inhibitor (e.g., fluconazole, mifepristone) or a moderate CYP450 2C9 inhibitor (e.g., abiraterone, amiodarone, fenofibrate, gemfibrozil, nitisinone, oxandrolone) in combination with a moderate or strong CYP450 3A4 inhibitor (e.g., amprenavir, aprepitant, atazanavir, boceprevir, ceritinib, chloramphenicol, ciprofloxacin, clarithromycin, cobicistat, conivaptan, crizotinib, dalfopristin-quinupristin, darunavir, delavirdine, diltiazem, dronedarone, erythromycin, fedratinib, fluvoxamine, fosamprenavir, fosaprepitant, fosnetupitant, fusidic acid, idelalisib, imatinib, indinavir, isavuconazole, itraconazole, ketoconazole, letermovir, mibefradil, nefazodone, nelfinavir, netupitant, posaconazole, ribociclib, ritonavir, saquinavir, stiripentol, telaprevir, telithromycin, troleandomycin, verapamil, voriconazole, voxelotor) is not recommended.  Caution is advised if siponimod is used in combination with moderate CYP450 2C9 inhibitors.', 'Metabolism', 'Concomitant use of siponimod with a moderate or strong CYP450 2C9/3A4 dual inhibitor (e.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297661/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Abatacept, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251318, 'Dalfopristin', 'Sirolimus', 'Moderate', 'Coadministration with drugs that are inhibitors of CYP450 3A4 may increase the blood concentrations of the macrolide immunosuppressants sirolimus and tacrolimus, both of which are metabolized by the isoenzyme.', 'DDInter', 'The possibility of prolonged and/or increased pharmacologic effects of macrolide immunosuppressant therapy should be considered, including adverse effects such as fever, infection, diarrhea, hypokalemia, anemia, thrombocytopenia, leukopenia, and hyperlipidemia.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy.', 'Metabolism', 'The possibility of prolonged and/or increased pharmacologic effects of macrolide immunosuppressant therapy should be considered, including adverse effects such as fever, infection, diarrhea, hypokalemia, anemia, thrombocytopenia, leukopenia, and hyperlipidemia.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297662/', '', 'Alteplase, Ascorbic acid, Vitamin A, Potassium Iodide, Acetylcysteine, Nandrolone, Heparin, Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251319, 'Dalfopristin', 'Solifenacin', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of solifenacin, which is primarily metabolized by the isoenzyme.', 'DDInter', 'Pharmacologic response to solifenacin should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the solifenacin dosage adjusted if necessary.  Patients should be advised to contact their physician if they experience undue adverse effects of solifenacin such as severe abdominal pain or constipation for 3 or more days.  Patients should seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.', 'Metabolism', 'Pharmacologic response to solifenacin should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the solifenacin dosage adjusted if necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297665/', '', 'Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251320, 'Dalfopristin', 'Sonidegib', 'Major', 'Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of sonidegib, which is primarily metabolized by the isoenzyme.', 'DDInter', 'Concomitant use of sonidegib with moderate CYP450 3A4 inhibitors should generally be avoided.  If coadministration is required, the manufacturer recommends limiting use of the moderate CYP450 3A4 inhibitor to less than 14 days and monitoring for adverse reactions, particularly musculoskeletal toxicity.', 'Metabolism', 'Concomitant use of sonidegib with moderate CYP450 3A4 inhibitors should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297666/', '', 'Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251321, 'Dalfopristin', 'Stiripentol', 'Moderate', 'Coadministration with inhibitors of CYP450 1A2, 2C19, and/or 3A4 may increase the plasma concentrations of stiripentol, which has been shown in vitro to undergo phase I metabolism via these pathways.', 'DDInter', 'Caution is advised when stiripentol is used with CYP450 1A2, 2C19, and/or 3A4 inhibitors.  Patients should be monitored for potentially increased adverse effects such as anorexia, nausea, vomiting, weight loss, somnolence, dizziness, confusion, difficulty concentrating, ataxia, hypotonia, tremor, hyperkinesia, dysarthria, suicidal ideation/behaviour, neutropenia, and thrombocytopenia.  Dosage adjustments for stiripentol or alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'Caution is advised when stiripentol is used with CYP450 1A2, 2C19, and/or 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297668/', '', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Phenytoin, Lacosamide, Levetiracetam, Oxcarbazepine, Ethotoin, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251322, 'Dalfopristin', 'Sufentanil', 'Moderate', 'Based on in vitro inhibition data, coadministration with dalfopristin-quinupristin may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme.  The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by dalfopristin-quinupristin.', 'DDInter', 'Caution is advised if dalfopristin-quinupristin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dalfopristin-quinupristin is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if dalfopristin-quinupristin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297669/', '', 'Halothane, Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251323, 'Dalfopristin', 'Suvorexant', 'Major', 'Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of suvorexant, which is primarily metabolized by the isoenzyme.', 'DDInter', 'The recommended dose of suvorexant is 5 mg when used with moderate CYP450 3A4 inhibitors, and generally should not exceed 10 mg.', 'Metabolism', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297670/', '', 'Methohexital, Methylphenobarbital, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Butabarbital, Secobarbital, Chloral hydrate, Quazepam, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251324, 'Dalfopristin', 'Tacrolimus', 'Major', 'Based on in vitro inhibition data, coadministration with dalfopristin-quinupristin may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme, including certain agents that can cause prolongation of the QTc interval (e.g., cisapride, disopyramide, pimozide, quinidine, tacrolimus).', 'DDInter', 'Given the potential for serious and life-threatening adverse cardiac events associated with increased plasma levels of agents that may prolong the QTc interval, concomitant use with dalfopristin-quinupristin should be avoided if they are known to be substrates of CYP450 3A4.', 'Metabolism', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297671/', '', 'Minoxidil, Deoxycholic acid, Calcium gluconate, Magnesium sulfate, Glycopyrronium, Pimecrolimus, Aminobenzoic acid, Finasteride, Ivermectin, Caffeine, Diclofenac, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251325, 'Dalfopristin', 'Tadalafil', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of tadalafil, which is primarily metabolized by the isoenzyme.', 'DDInter', 'Caution is advised if tadalafil is prescribed with CYP450 3A4 inhibitors.  Dosage adjustments may be appropriate for tadalafil whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy based on efficacy and side effects.  Tadalafil labeling recommends that the dosage not exceed 10 mg once every 72 hours in patients treated concomitantly with a potent CYP450 3A4 inhibitor, such as erythromycin, itraconazole, ketoconazole, protease inhibitors, and nefazodone.  Patients should be advised to promptly notify their physician if they experience potential symptoms of PDE5 inhibitor toxicity such as pain or tightness in the chest or jaw, irregular heartbeat, nausea, shortness of breath, visual disturbances, syncope, or prolonged erection (greater than 4 hours).', 'Metabolism', 'Caution is advised if tadalafil is prescribed with CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297672/', '', 'Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251326, 'Dalfopristin', 'Tamoxifen', 'Major', 'Based on in vitro inhibition data, coadministration with dalfopristin-quinupristin may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme, including certain agents that can cause prolongation of the QTc interval (e.g., cisapride, disopyramide, pimozide, quinidine, tacrolimus).', 'DDInter', 'Given the potential for serious and life-threatening adverse cardiac events associated with increased plasma levels of agents that may prolong the QTc interval, concomitant use with dalfopristin-quinupristin should be avoided if they are known to be substrates of CYP450 3A4.', 'Metabolism', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297673/', '', 'Anastrozole, Aminoglutethimide, Letrozole, Fulvestrant, Abarelix, Flutamide, Relugolix, Bicalutamide, Degarelix, Nilutamide, Apalutamide, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251327, 'Dalfopristin', 'Tamsulosin', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or 2D6 may increase the plasma concentrations of tamsulosin, which is primarily metabolized in the liver by these isoenzymes.', 'DDInter', 'Caution is advised if tamsulosin is used concomitantly with moderate CYP450 3A4 inhibitors (e.g., amiodarone, aprepitant, diltiazem, dronedarone, erythromycin, fluconazole, fluvoxamine, fusidic acid, imatinib, isavuconazonium, verapamil) and/or moderate to potent CYP450 2D6 inhibitors (e.g., abiraterone, bupropion, celecoxib, cinacalcet, darifenacin, dronedarone, duloxetine, fluoxetine, lorcaserin, paroxetine, propafenone, quinidine, ranolazine, rolapitant, terbinafine), particularly at a dosage higher than 0.4 mg/day.  The potential for increased risk of adverse effects such as postural hypotension, syncope, and priapism should be considered.  It should be noted that rolapitant, a moderate CYP450 2D6 inhibitor, can increase plasma concentrations and the risk of adverse effects of tamsulosin for at least 28 days after administration of rolapitant.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position, and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  Patients should also avoid driving or operating hazardous machinery until they know how the medication affects them.', 'Metabolism', 'Caution is advised if tamsulosin is used concomitantly with moderate CYP450 3A4 inhibitors (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297674/', '', 'Finasteride, Terazosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251328, 'Dalfopristin', 'Tasimelteon', 'Moderate', 'Coadministration with inhibitors of CYP450 1A2 and/or 3A4 may increase the plasma concentrations of tasimelteon, which is primarily metabolized by these isoenzymes.', 'DDInter', 'Caution is advised if tasimelteon is prescribed in combination with inhibitors of CYP450 1A2 and/or 3A4.  Patients should be monitored for excessive sedation and other side effects.', 'Metabolism', 'Caution is advised if tasimelteon is prescribed in combination with inhibitors of CYP450 1A2 and/or 3A4.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297675/', '', 'Methohexital, Methylphenobarbital, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Butabarbital, Secobarbital, Chloral hydrate, Quazepam, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251329, 'Dalfopristin', 'Tazemetostat', 'Major', 'Coadministration with moderate or potent CYP450 3A4 inhibitors may significantly increase the plasma concentrations of tazemetostat, which is primarily metabolized by the isoenzyme.', 'DDInter', 'Concomitant use of tazemetostat with moderate or potent CYP450 3A4 inhibitors should generally be avoided.  Alternative therapeutic agents with less inhibitory potential should be considered whenever possible.  If coadministration with a moderate CYP450 3A4 inhibitor is required and no other alternatives are possible, the dose of tazemetostat should be reduced as per manufacturer recommendations.  After the inhibitor has been discontinued for 3 elimination half-lives, the tazemetostat dose that was taken prior to initiating the inhibitor may be resumed.  Patients should be advised to notify their health care professional if they experience signs or symptoms of possible tazemetostat-related adverse effects including secondary malignancies, hemorrhage, pleural effusion, skin infection, dyspnea, pain, and respiratory distress.', 'Metabolism', 'Concomitant use of tazemetostat with moderate or potent CYP450 3A4 inhibitors should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297676/', '', 'Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251330, 'Dalfopristin', 'Temsirolimus', 'Moderate', 'Coadministration of temsirolimus with inhibitors of CYP450 3A4 may increase the plasma concentrations of sirolimus, a major active metabolite of temsirolimus and known substrate of CYP450 3A4.', 'DDInter', 'Caution is advised if temsirolimus is prescribed in combination with CYP450 3A4 inhibitors.  Pharmacologic response to temsirolimus should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the temsirolimus dosage adjusted as necessary.  Patients should be advised to contact their physician if they experience increased adverse effects of temsirolimus such as hyperglycemia (e.g., excessive thirst; increased volume and/or frequency of urination), infections, fever, dyspnea, abdominal pain, diarrhea, and bloody stools.', 'Metabolism', 'Caution is advised if temsirolimus is prescribed in combination with CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297677/', '', 'Dabrafenib, Dacomitinib, Vemurafenib, Vandetanib, Afatinib, Tivozanib, Sunitinib, Regorafenib, Alpelisib, Lenvatinib, Erlotinib, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251331, 'Dalfopristin', 'Terfenadine', 'Major', 'Based on in vitro inhibition data, coadministration with dalfopristin-quinupristin may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme, including certain agents that can cause prolongation of the QTc interval (e.g., cisapride, disopyramide, pimozide, quinidine, tacrolimus).', 'DDInter', 'Given the potential for serious and life-threatening adverse cardiac events associated with increased plasma levels of agents that may prolong the QTc interval, concomitant use with dalfopristin-quinupristin should be avoided if they are known to be substrates of CYP450 3A4.', 'Metabolism', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297679/', '', 'Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Promethazine, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251332, 'Dalfopristin', 'Testosterone', 'Moderate', 'Based on in vitro inhibition data, coadministration with dalfopristin-quinupristin may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme.  The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by dalfopristin-quinupristin.', 'DDInter', 'Caution is advised if dalfopristin-quinupristin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dalfopristin-quinupristin is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if dalfopristin-quinupristin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297680/', '', 'Methyltestosterone, Fluoxymesterone, Prasterone, Methyltestosterone', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251333, 'Dalfopristin', 'Testosterone (topical)', 'Moderate', 'Based on in vitro inhibition data, coadministration with dalfopristin-quinupristin may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme.  The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by dalfopristin-quinupristin.', 'DDInter', 'Caution is advised if dalfopristin-quinupristin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dalfopristin-quinupristin is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if dalfopristin-quinupristin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297681/', '', 'Methyltestosterone, Fluoxymesterone, Prasterone, Methyltestosterone', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251334, 'Dalfopristin', 'Tiagabine', 'Moderate', 'Based on in vitro inhibition data, coadministration with dalfopristin-quinupristin may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme.  The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by dalfopristin-quinupristin.', 'DDInter', 'Caution is advised if dalfopristin-quinupristin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dalfopristin-quinupristin is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if dalfopristin-quinupristin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297682/', '', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Phenytoin, Lacosamide, Levetiracetam, Oxcarbazepine, Ethotoin, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251335, 'Dalfopristin', 'Ticagrelor', 'Moderate', 'Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of ticagrelor, which is primarily metabolized by the isoenzyme.', 'DDInter', 'Although administration with moderate CYP450 3A4 inhibitors is thought to be generally safe, it may be advisable to monitor pharmacologic response to ticagrelor more closely following the addition and withdrawal of these agents.  Discontinuation of the concomitant medication may be required if an interaction is suspected.', 'Metabolism', 'Although administration with moderate CYP450 3A4 inhibitors is thought to be generally safe, it may be advisable to monitor pharmacologic response to ticagrelor more closely following the addition and withdrawal of these agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297683/', '', 'Betrixaban, Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Warfarin, Caplacizumab, Argatroban, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251336, 'Dalfopristin', 'Tofacitinib', 'Moderate', 'Coadministration with one or more medications that may result in both moderate inhibition of CYP450 3A4 and potent inhibition of CYP450 2C19 may significantly increase the plasma concentrations of tofacitinib, which is primarily metabolized by the former isoenzyme with minor contribution from the latter.', 'DDInter', 'The dosage of tofacitinib should be reduced by 50% when used concomitantly with one or more medications that may result in both moderate inhibition of CYP450 3A4 and potent inhibition of CYP450 2C19.  For example, the dose for patients receiving 10 mg twice daily should be reduced to 5 mg twice daily and the dose for patients receiving 5 mg twice daily should be reduced to 5 mg once daily.  For patients receiving 11 mg once daily of the extended-release formulation, the dose should be reduced to 5 mg once daily of the immediate-release formulation.  The dose for patients receiving 3.2 mg twice daily should be reduced to 3.2 mg once daily and the dose for patients receiving 4 mg twice daily should be reduced to 4 mg once daily.  Moderate inhibitors of CYP450 3A4 include amiodarone, aprepitant, ciprofloxacin, crizotinib, darunavir, dalfopristin-quinupristin, diltiazem, dronedarone, erythromycin, fluconazole, fusidic acid, grapefruit juice, imatinib, isavuconazonium, netupitant, and verapamil.  Potent inhibitors of CYP450 2C19 include fluconazole, fluvoxamine, esomeprazole, lansoprazole, and omeprazole.  Inhibitors of CYP450 2C19 alone are unlikely to substantially alter the pharmacokinetics of tofacitinib.', 'Metabolism', 'The dosage of tofacitinib should be reduced by 50% when used concomitantly with one or more medications that may result in both moderate inhibition of CYP450 3A4 and potent inhibition of CYP450 2C19.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297685/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Abatacept, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251337, 'Dalfopristin', 'Tolterodine', 'Moderate', 'Coadministration with drugs that are inhibitors of CYP450 3A4 may increase the plasma concentrations of tolterodine, which is partially metabolized by the isoenzyme.  The possibility of prolonged and/or increased pharmacologic effects of tolterodine should be considered.  Although tolterodine is primarily metabolized by CYP450 2D6, there is some evidence that CYP450 3A4 may play a minor role, thus any alteration in its activity levels could conceivably affect the metabolism of tolterodine.', 'DDInter', 'The manufacturer recommends a maximum tolterodine dosage of 1 mg twice daily in patients receiving concomitant CYP450 3A4 inhibitors.  Close clinical and laboratory monitoring is advised whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy.  Patients should be advised to notify their physician if they experience an irregular heartbeat, severe blurry vision, difficulty urinating, dry mouth, headache, drowsiness, dizziness, or GI upset.', 'Metabolism', 'The manufacturer recommends a maximum tolterodine dosage of 1 mg twice daily in patients receiving concomitant CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297686/', '', 'Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251338, 'Dalfopristin', 'Tolvaptan', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of tolvaptan, which is almost exclusively metabolized by the isoenzyme.', 'DDInter', 'Concomitant use of tolvaptan with moderate CYP450 3A4 inhibitors should generally be avoided unless no alternatives exist and benefits outweigh potential risks.  A lower dosage of tolvaptan should be considered.  Serum sodium concentration and neurologic status should be closely monitored during coadministration.  Too rapid correction of hyponatremia increases the risk of osmotic demyelination syndrome, which is associated with dysarthria, mutism, dysphagia, lethargy, affective changes, spastic quadriparesis, seizures, coma, and death.  Discontinuation or interruption of tolvaptan therapy should be considered in patients who develop too rapid a rise in serum sodium.', 'Metabolism', 'Concomitant use of tolvaptan with moderate CYP450 3A4 inhibitors should generally be avoided unless no alternatives exist and benefits outweigh potential risks.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297687/', '', 'Conivaptan', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251339, 'Dalfopristin', 'Toremifene', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of toremifene, which is primarily metabolized by the isoenzyme.', 'DDInter', 'Clinical and laboratory monitoring for altered efficacy and safety of toremifene may be appropriate whenever a CYP450 3A inhibitor is added to or withdrawn from therapy.  Complete blood counts, electrolyte levels (calcium, magnesium, potassium), and liver function tests should be obtained periodically.  Patients should be advised to contact their physician if they experience vaginal bleeding or potential signs of blood clots such as chest pain, shortness of breath, sudden loss of vision, and pain, redness or swelling in an extremity.  Patients should seek immediate medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope.', 'Metabolism', 'Clinical and laboratory monitoring for altered efficacy and safety of toremifene may be appropriate whenever a CYP450 3A inhibitor is added to or withdrawn from therapy.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297688/', '', 'Anastrozole, Aminoglutethimide, Letrozole, Fulvestrant, Abarelix, Flutamide, Relugolix, Bicalutamide, Degarelix, Nilutamide, Apalutamide, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251340, 'Dalfopristin', 'Trabectedin', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme.', 'DDInter', 'Caution is advised when trabectedin is prescribed with CYP450 3A4 inhibitors.  Patients should be monitored for toxicities such as myelosuppression, rhabdomyolysis, hepatotoxicity, and cardiomyopathy, and the trabectedin dosage adjusted accordingly or treatment discontinued as necessary.', 'Metabolism', 'Caution is advised when trabectedin is prescribed with CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297689/', '', 'Topotecan, Teniposide', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251341, 'Dalfopristin', 'Tramadol', 'Moderate', 'Coadministration with drugs that are inhibitors of the CYP450 3A4 isoenzymes may increase the plasma concentrations of tramadol and its active O-demethylated metabolite.', 'DDInter', 'Caution is advised if tramadol is used concomitantly with medications that inhibit CYP450 3A4 metabolism.  Dosage adjustments as well as clinical monitoring may be appropriate whenever there drugs are added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if tramadol is used concomitantly with medications that inhibit CYP450 3A4 metabolism.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297690/', '', 'Codeine, Morphine, Naltrexone, Oxymorphone, Tapentadol, Meperidine, Hydromorphone, Acetaminophen, Dezocine, Opium, Dextropropoxyphene, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251342, 'Dalfopristin', 'Triamcinolone', 'Moderate', 'Based on in vitro inhibition data, coadministration with dalfopristin-quinupristin may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme.  The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by dalfopristin-quinupristin.', 'DDInter', 'Caution is advised if dalfopristin-quinupristin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dalfopristin-quinupristin is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if dalfopristin-quinupristin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297691/', '', 'Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluocinonide, Fluorometholone, Clobetasol, Beclomethasone dipropionate, Ciclesonide, Mupirocin, Mometasone furoate, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251343, 'Dalfopristin', 'Triazolam', 'Moderate', 'Based on in vitro inhibition data, coadministration with dalfopristin-quinupristin may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme.  The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by dalfopristin-quinupristin.', 'DDInter', 'Caution is advised if dalfopristin-quinupristin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dalfopristin-quinupristin is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if dalfopristin-quinupristin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297692/', '', 'Methohexital, Methylphenobarbital, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Butabarbital, Secobarbital, Chloral hydrate, Quazepam, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251344, 'Dalfopristin', 'Troleandomycin', 'Moderate', 'Based on in vitro inhibition data, coadministration with dalfopristin-quinupristin may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme.  The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by dalfopristin-quinupristin.', 'DDInter', 'Caution is advised if dalfopristin-quinupristin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dalfopristin-quinupristin is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if dalfopristin-quinupristin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297693/', '', 'Clindamycin, Telithromycin, Dirithromycin, Azithromycin, Lincomycin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251345, 'Dalfopristin', 'Ubrogepant', 'Moderate', 'Coadministration with moderate or weak inhibitors of CYP450 3A4 may increase the plasma concentrations of ubrogepant, which is primarily metabolized by the isoenzyme.', 'DDInter', 'The manufacturer recommends an initial ubrogepant dose of 50 mg when coadministered with moderate or weak CYP450 3A4 inhibitors.  If needed, a second ubrogepant dose should be avoided within 24 hours of the initial dose when used with moderate CYP450 3A4 inhibitors.  When used with weak CYP450 3A4 inhibitors, a second 50 mg dose of ubrogepant may be administered at least 2 hours after the initial dose, if needed.', 'Metabolism', 'The manufacturer recommends an initial ubrogepant dose of 50 mg when coadministered with moderate or weak CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297695/', '', 'Frovatriptan, Eptinezumab, Lasmiditan, Rizatriptan, Naratriptan, Galcanezumab, Zolmitriptan, Sumatriptan, Erenumab, Clonidine, Almotriptan, Fremanezumab', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251346, 'Dalfopristin', 'Ulipristal', 'Minor', 'Coadministration with CYP450 3A4 inhibitors may increase the plasma concentrations of ulipristal, which is primarily metabolized by the isoenzyme.', 'DDInter', 'Coadministration with CYP450 3A4 inhibitors may increase the plasma concentrations of ulipristal, which is primarily metabolized by the isoenzyme.  The clinical relevance is unknown.', 'Metabolism', 'Coadministration with CYP450 3A4 inhibitors may increase the plasma concentrations of ulipristal, which is primarily metabolized by the isoenzyme.', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297696/', '', 'Norelgestromin, Megestrol acetate, Norgestimate, Etynodiol, Levonorgestrel, Desogestrel, Dienogest, Estetrol, Etonogestrel, Norgestrel, Raloxifene, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251347, 'Dalfopristin', 'Upadacitinib', 'Moderate', 'Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of upadacitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 'Caution is recommended if upadacitinib is used with moderate CYP450 3A4 inhibitors.  Pharmacologic effects of upadacitinib should be monitored more closely whenever a moderate CYP450 3A4 inhibitor is added to or withdrawn from therapy.', 'Metabolism', 'Caution is recommended if upadacitinib is used with moderate CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297697/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Abatacept, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251348, 'Dalfopristin', 'Valdecoxib', 'Moderate', 'Coadministration with inhibitors of CYP450 2C9 and/or 3A4 may increase the plasma concentrations of valdecoxib, which is metabolized by these isoenzymes.', 'DDInter', 'The possibility of prolonged and/or increased pharmacologic effects of valdecoxib or parecoxib, including serious adverse effects such as gastrointestinal ulceration and bleeding, should be considered during concomitant therapy with CYP450 2C9 or 3A4 inhibitors, particularly combination (2C9/3A4) inhibitors such as fluconazole, fluvoxamine, imatinib, and zafirlukast.  Dose reductions of the COX-2 inhibitor may be required.', 'Metabolism', 'The possibility of prolonged and/or increased pharmacologic effects of valdecoxib or parecoxib, including serious adverse effects such as gastrointestinal ulceration and bleeding, should be considered during concomitant therapy with CYP450 2C9 or 3A4 inhibitors, particularly combination (2C9/3A4) inhibitors such as fluconazole, fluvoxamine, imatinib, and zafirlukast.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297698/', '', 'Rabeprazole, Ketoprofen, Diclofenac, Piroxicam, Rofecoxib, Sulindac, Meclofenamic acid, Etodolac, Ketorolac, Misoprostol, Glucosamine, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251349, 'Dalfopristin', 'Vardenafil', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or 2C9 may increase the plasma concentrations of vardenafil, which is primarily metabolized by the former and secondarily by the latter.', 'DDInter', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance.  The manufacturer recommends that an initial vardenafil dosage of 2.5 to 5 mg be used in patients treated concomitantly with a potent CYP450 3A4 inhibitor such as erythromycin, itraconazole, ketoconazole, indinavir, and ritonavir.  No specific dosage recommendations are available for coadministration with less potent inhibitors.  Patients should be advised to promptly notify their doctor if they experience pain or tightness in the chest or jaw, irregular heartbeat, nausea, shortness of breath, visual disturbances, syncope, or prolonged erection (greater than 4 hours).', 'Metabolism', 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297699/', '', 'Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251350, 'Dalfopristin', 'Venetoclax', 'Major', 'Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of venetoclax, which is a substrate of the isoenzyme.', 'DDInter', 'Concomitant use of venetoclax with moderate CYP450 3A4 inhibitors should generally be avoided.  If coadministration is required, the manufacturer recommends that venetoclax dosage be reduced by at least 50%.  The dosage used prior to initiating the CYP450 3A4 inhibitor may be resumed 2 to 3 days after discontinuation of the inhibitor.', 'Metabolism', 'Concomitant use of venetoclax with moderate CYP450 3A4 inhibitors should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297700/', '', 'Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251351, 'Dalfopristin', 'Venlafaxine', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of venlafaxine and its metabolite, O-desmethylvenlafaxine (ODV).', 'DDInter', 'Caution is recommended when venlafaxine is used with CYP450 3A4 inhibitors.', 'Metabolism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297701/', '', 'Maprotiline, Fluoxetine, St. John''s Wort, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Viloxazine, Amoxapine, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251352, 'Dalfopristin', 'Verapamil', 'Moderate', 'Based on in vitro inhibition data, coadministration with dalfopristin-quinupristin may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme.  The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by dalfopristin-quinupristin.', 'DDInter', 'Caution is advised if dalfopristin-quinupristin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dalfopristin-quinupristin is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if dalfopristin-quinupristin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297702/', '', 'Enalapril, Moexipril, Ramipril, Hydrochlorothiazide, Lisinopril, Perindopril, Bisoprolol, Benazepril, Quinapril, Trandolapril, Captopril, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251353, 'Dalfopristin', 'Vilazodone', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of vilazodone, which is primarily metabolized by the isoenzyme.', 'DDInter', 'When used with moderate CYP450 3A4 inhibitors, the maintenance dosage of vilazodone should be reduced to 20 mg/day in patients who develop intolerable adverse events.', 'Metabolism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297703/', '', 'Maprotiline, Fluoxetine, St. John''s Wort, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Viloxazine, Amoxapine, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251354, 'Dalfopristin', 'Vinblastine', 'Moderate', 'Based on in vitro inhibition data, coadministration with dalfopristin-quinupristin may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme.  The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by dalfopristin-quinupristin.', 'DDInter', 'Caution is advised if dalfopristin-quinupristin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dalfopristin-quinupristin is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if dalfopristin-quinupristin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297704/', '', 'Topotecan, Teniposide', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251355, 'Dalfopristin', 'Vincristine', 'Moderate', 'Based on in vitro inhibition data, coadministration with dalfopristin-quinupristin may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme.  The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by dalfopristin-quinupristin.', 'DDInter', 'Caution is advised if dalfopristin-quinupristin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dalfopristin-quinupristin is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if dalfopristin-quinupristin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297705/', '', 'Topotecan, Teniposide', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251356, 'Dalfopristin', 'Vincristine (liposome)', 'Moderate', 'Based on in vitro inhibition data, coadministration with dalfopristin-quinupristin may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme.  The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by dalfopristin-quinupristin.', 'DDInter', 'Caution is advised if dalfopristin-quinupristin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dalfopristin-quinupristin is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if dalfopristin-quinupristin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297706/', '', 'Topotecan, Teniposide', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251357, 'Dalfopristin', 'Vinorelbine', 'Moderate', 'Based on in vitro inhibition data, coadministration with dalfopristin-quinupristin may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme.  The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by dalfopristin-quinupristin.', 'DDInter', 'Caution is advised if dalfopristin-quinupristin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dalfopristin-quinupristin is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if dalfopristin-quinupristin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297707/', '', 'Topotecan, Teniposide', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251358, 'Dalfopristin', 'Voxelotor', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the systemic exposure (AUC) to voxelotor, which has been shown to be a substrate of this isoenzyme.', 'DDInter', 'Caution is recommended if voxelotor is to be used with a CYP450 3A4 inhibitor.  Dose adjustments may be necessary.  Patients should be closely monitored for signs of voxelotor-related adverse effects, including headache, diarrhea, abdominal pain, nausea, and vomiting.', 'Metabolism', 'Caution is recommended if voxelotor is to be used with a CYP450 3A4 inhibitor.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297709/', '', 'Hemin, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251359, 'Dalfopristin', 'Zanubrutinib', 'Major', 'Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of zanubrutinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 'The manufacturer recommends reducing the dosage of zanubrutinib to 80 mg twice daily when coadministered with moderate CYP450 3A4 inhibitors.  Patients should be closely monitored for development of zanubrutinib-related toxicities, and further dosage adjustments made or treatment withheld as needed in accordance with the product labeling.  Following discontinuation of the CYP450 3A4 inhibitor, the previous dosage of zanubrutinib should be resumed.', 'Metabolism', 'The manufacturer recommends reducing the dosage of zanubrutinib to 80 mg twice daily when coadministered with moderate CYP450 3A4 inhibitors.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297710/', '', 'Dabrafenib, Dacomitinib, Vemurafenib, Vandetanib, Afatinib, Tivozanib, Sunitinib, Regorafenib, Alpelisib, Lenvatinib, Erlotinib, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251360, 'Dalfopristin', 'Zileuton', 'Moderate', 'Based on in vitro inhibition data, coadministration with dalfopristin-quinupristin may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme.  The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by dalfopristin-quinupristin.', 'DDInter', 'Caution is advised if dalfopristin-quinupristin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dalfopristin-quinupristin is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if dalfopristin-quinupristin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297711/', '', '', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251361, 'Dalfopristin', 'Ziprasidone', 'Minor', 'Coadministration with inhibitors of CYP450 3A4 may only modestly increase the plasma concentrations of ziprasidone, as less than 1/3 of ziprasidone metabolic clearance occurs via oxidation mediated by CYP450 3A4.', 'DDInter', 'Coadministration with inhibitors of CYP450 3A4 may only modestly increase the plasma concentrations of ziprasidone, as less than 1/3 of ziprasidone metabolic clearance occurs via oxidation mediated by CYP450 3A4.  In 14 healthy subjects, coadministration with the potent CYP450 3A4 inhibitor ketoconazole (400 mg orally once a day for 5 days) increased the mean peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) of ziprasidone (40 mg single oral dose) by approximately 1/3 compared to placebo.  These changes, although statistically significant, were not considered clinically important.  There were also no serious adverse events, laboratory or ECG abnormalities, or clinically significant alterations in vital signs throughout the study.  Likewise, in 10 healthy subjects, the nonspecific CYP450 inhibitor cimetidine (800 mg orally once a day for 3 days) increased the AUC of ziprasidone (40 mg single oral dose) by just 6% compared to when ziprasidone was administered alone.  These findings suggest that ziprasidone dose modifications are unlikely to be necessary in patients receiving potent CYP450 3A4 inhibitors.', 'Metabolism', 'Coadministration with inhibitors of CYP450 3A4 may only modestly increase the plasma concentrations of ziprasidone, as less than 1/3 of ziprasidone metabolic clearance occurs via oxidation mediated by CYP450 3A4.', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297712/', '', 'Fluphenazine, Haloperidol, Thiothixene, Risperidone, Amisulpride, Prochlorperazine, Promazine, Thioridazine, Trifluoperazine, Paliperidone, Chlorpromazine, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251362, 'Dalfopristin', 'Zolpidem', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of zolpidem, which is partially metabolized by the isoenzyme.', 'DDInter', 'Caution is advised when zolpidem is used with CYP450 3A4 inhibitors.  Patients should be advised to avoid driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how the medications affect them, and to notify their physician if they experience excessive somnolence or dizziness.', 'Metabolism', 'Caution is advised when zolpidem is used with CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297713/', '', 'Methohexital, Methylphenobarbital, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Butabarbital, Secobarbital, Chloral hydrate, Quazepam, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251363, 'Dalfopristin', 'Zonisamide', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of zonisamide, which is metabolized by the isoenzyme.', 'DDInter', 'Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy.  Patients should be advised to notify their physician if they experience symptoms such as severe drowsiness, confusion, loss of coordination, depression, aphasia, decreased sweating, fever, loss of seizure control, or slow pulse.', 'Metabolism', 'Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297714/', '', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Phenytoin, Lacosamide, Levetiracetam, Oxcarbazepine, Ethotoin, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251364, 'Dapagliflozin', 'Brentuximab vedotin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 'Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.', 'Antagonism', 'Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297715/', '', 'Guar gum', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251365, 'Dapagliflozin', 'Nitroprusside', 'Moderate', 'Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators.  Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction.', 'DDInter', 'Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.  Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary.  Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure.  If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.', 'Synergism', 'Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297717/', '', 'Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Dulaglutide, Exenatide, Tolbutamide, Miglitol, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251366, 'Dapagliflozin', 'Somapacitan', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 'Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.', 'Antagonism', 'Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297718/', '', 'Guar gum, Rosuvastatin', 'Mecasermin, Mecasermin rinfabate', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251367, 'Dapagliflozin', 'Thyrotropin alfa', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 'Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.', 'Antagonism', 'Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297719/', '', 'Simvastatin, Guar gum, Rosuvastatin', 'Mecasermin, Mecasermin rinfabate', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251368, 'Brentuximab vedotin', 'Saxagliptin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 'Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.', 'Antagonism', 'Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297720/', '', 'Guar gum', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251369, 'Somapacitan', 'Saxagliptin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 'Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.', 'Antagonism', 'Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297723/', '', 'Guar gum, Rosuvastatin', 'Mecasermin, Mecasermin rinfabate', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251370, 'St. John''s Wort', 'Saxagliptin', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of saxagliptin, which is primarily metabolized by the isoenzyme.', 'DDInter', 'Dosage adjustment of saxagliptin is not necessary during coadministration with rifampin or other CYP450 3A4 inducers.  However, glycemic control should be closely monitored, and the physician notified if an interaction is suspected.', 'Metabolism', 'Dosage adjustment of saxagliptin is not necessary during coadministration with rifampin or other CYP450 3A4 inducers.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297724/', '', 'Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, More', 'Citalopram, Sertraline, Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Amoxapine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251371, 'Telotristat ethyl', 'Saxagliptin', 'Moderate', 'Coadministration with telotristat ethyl may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or 2B6 isoenzymes.  The proposed mechanism is accelerated clearance due to induction of CYP450 3A4 and/or 2B6 (in vitro) isoenzymes by telotristat ethyl.', 'DDInter', 'When drugs that are known substrates of CYP450 3A4 and/or 2B6 are coadministered with telotristat ethyl, the possibility of a diminished therapeutic response to those drugs should be considered.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever telotristat ethyl is added to or withdrawn from therapy.', 'Metabolism', 'When drugs that are known substrates of CYP450 3A4 and/or 2B6 are coadministered with telotristat ethyl, the possibility of a diminished therapeutic response to those drugs should be considered.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297726/', '', 'Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251372, 'Thyrotropin alfa', 'Saxagliptin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 'Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.', 'Antagonism', 'Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297727/', '', 'Simvastatin, Guar gum, Rosuvastatin', 'Mecasermin, Mecasermin rinfabate', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251373, 'Human adenovirus e serotype 4 strain cl-68578 antigen', 'Daratumumab', 'Moderate', 'There are no data regarding the use of live, unattenuated Adenovirus Type 4 and Type 7 vaccine during treatment with immunosuppressive therapies, including alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.  It is not known whether immunosuppressed patients may have an increased risk of adverse reactions or a decreased or suboptimal immunologic response to the vaccine.', 'DDInter', 'The safety and efficacy of live, unattenuated Adenovirus Type 4 and Type 7 vaccine have not been established in patients receiving immunosuppressive therapies.  Caution is advised.', 'Others', 'The safety and efficacy of live, unattenuated Adenovirus Type 4 and Type 7 vaccine have not been established in patients receiving immunosuppressive therapies.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297729/', '', 'Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251374, 'Influenza A virus A/Vietnam/1194/2004 (H5N1) antigen (formaldehyde inactivated)', 'Daratumumab', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.', 'DDInter', 'In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual''s risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', 'In general, the U.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297730/', '', 'Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251375, 'Daratumumab', 'Radium Ra 223 dichloride', 'Moderate', 'The concomitant use of bone marrow depressants and radium Ra 223 dichloride may have additive myelosuppressive effects.', 'DDInter', 'Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride.  Dose reductions of the other bone marrow depressants may be necessary.  Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.  The safety and efficacy of concomitant use of chemotherapy have not been established.  Outside of a clinical trial, concomitant use with chemotherapy is not recommended due to the potential for additive myelosuppression.  If chemotherapy, other systemic radioisotopes or hemibody external radiotherapy are administered during the treatment period, radium Ra 223 should be discontinued.', 'Synergism', 'Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297733/', '', 'Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Dostarlimab, Amivantamab, Ramucirumab, Atezolizumab, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251376, 'Abametapir (topical)', 'Paritaprevir', 'Moderate', 'Based on in vitro inhibition data, a single topical application of abametapir lotion may increase plasma concentrations of drugs that are substrates of CYP450 3A4, CYP450 2B6, and CYP450 1A2 isoenzymes and increase their systemic concentrations.', 'DDInter', 'Use of CYP450 3A4, CYP450 2B6, and CYP450 1A2 substrates should generally be avoided within 2 weeks after topical application of abametapir lotion.  If this is not feasible, the manufacturer recommends avoiding use of abametapir lotion.  If abametapir is used, monitor for increased toxicity of the CYP450 3A4, CYP450 2B6, and/or CYP450 1A2 substrate.', 'Metabolism', 'Use of CYP450 3A4, CYP450 2B6, and CYP450 1A2 substrates should generally be avoided within 2 weeks after topical application of abametapir lotion.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297734/', '', 'Lamivudine, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Dolutegravir, Oseltamivir, Acyclovir, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251377, 'Abiraterone', 'Dasabuvir', 'Moderate', 'Coadministration with inhibitors of CYP450 2C8 may increase the plasma concentrations of dasabuvir, which is primarily metabolized by the isoenzyme.', 'DDInter', 'Caution is advised if dasabuvir is prescribed in combination with CYP450 2C8 inhibitors.  Patients should be monitored for development of hepatotoxicity (i.e., ALT elevations) and QT interval prolongation.', 'Metabolism', 'Caution is advised if dasabuvir is prescribed in combination with CYP450 2C8 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297735/', '', 'Tamoxifen, Anastrozole, Letrozole, Toremifene, Fulvestrant, Abarelix, Flutamide, Relugolix, Bicalutamide, Degarelix, Nilutamide, More', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Etravirine, Dolutegravir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251378, 'Paritaprevir', 'Acarbose', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297740/', '', 'Simvastatin, Guar gum, Rosuvastatin', 'Lamivudine, Tenofovir alafenamide, Cabotegravir, Maraviroc, Zanamivir, Lenacapavir, Telaprevir, Rilpivirine, Etravirine, Dolutegravir, Oseltamivir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251379, 'Dasabuvir', 'Acarbose', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297741/', '', 'Simvastatin, Guar gum, Rosuvastatin', 'Lamivudine, Tenofovir alafenamide, Cabotegravir, Maraviroc, Zanamivir, Lenacapavir, Telaprevir, Rilpivirine, Etravirine, Dolutegravir, Oseltamivir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251380, 'Acetohexamide', 'Paritaprevir', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297743/', '', 'Simvastatin, Guar gum, Rosuvastatin', 'Lamivudine, Tenofovir alafenamide, Maraviroc, Cabotegravir, Zanamivir, Valaciclovir, Lenacapavir, Telaprevir, Rilpivirine, Dolutegravir, Oseltamivir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251381, 'Dasabuvir', 'Acetohexamide', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297744/', '', 'Simvastatin, Guar gum, Rosuvastatin', 'Lamivudine, Tenofovir alafenamide, Maraviroc, Cabotegravir, Zanamivir, Valaciclovir, Lenacapavir, Telaprevir, Rilpivirine, Dolutegravir, Oseltamivir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251382, 'Albiglutide', 'Paritaprevir', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297748/', '', 'Simvastatin, Guar gum, Rosuvastatin', 'Lamivudine, Tenofovir alafenamide, Maraviroc, Cabotegravir, Zanamivir, Valaciclovir, Lenacapavir, Telaprevir, Rilpivirine, Etravirine, Dolutegravir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251383, 'Dasabuvir', 'Albiglutide', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297749/', '', 'Simvastatin, Guar gum, Rosuvastatin', 'Lamivudine, Tenofovir alafenamide, Maraviroc, Cabotegravir, Zanamivir, Valaciclovir, Lenacapavir, Telaprevir, Rilpivirine, Etravirine, Dolutegravir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251384, 'Alogliptin', 'Paritaprevir', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297751/', '', 'Simvastatin, Guar gum, Rosuvastatin', 'Lamivudine, Tenofovir alafenamide, Maraviroc, Cabotegravir, Zanamivir, Valaciclovir, Lenacapavir, Telaprevir, Rilpivirine, Etravirine, Dolutegravir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251385, 'Alogliptin', 'Dasabuvir', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297752/', '', 'Simvastatin, Guar gum, Rosuvastatin', 'Lamivudine, Tenofovir alafenamide, Maraviroc, Cabotegravir, Zanamivir, Valaciclovir, Lenacapavir, Telaprevir, Rilpivirine, Etravirine, Dolutegravir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251386, 'Alpelisib', 'Dasabuvir', 'Moderate', 'Coadministration of inhibitors of the breast cancer resistance protein (BCRP) transporter with alpelisib may increase the plasma concentrations and risk of adverse effects of alpelisib, which is a substrate of this efflux transporter.', 'DDInter', 'If coadministration with BCRP inhibitors is required, patients should be closely monitored for alpelisib-related adverse reactions, including hyperglycemia, diarrhea, rash, acute kidney injury, abdominal pain, and anemia.  Some authorities recommend coadministration of alpelisib with BCRP inhibitors be avoided whenever possible (US).', 'Excretion', 'If coadministration with BCRP inhibitors is required, patients should be closely monitored for alpelisib-related adverse reactions, including hyperglycemia, diarrhea, rash, acute kidney injury, abdominal pain, and anemia.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297753/', '', 'Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, Selumetinib, Vandetanib, Ibrutinib, More', 'Lamivudine, Paritaprevir, Glecaprevir, Simeprevir, Amprenavir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251387, 'Amprenavir', 'Paritaprevir', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of paritaprevir, which is primarily metabolized by the isoenzyme.', 'DDInter', 'Caution is advised if paritaprevir is prescribed in combination with potent CYP450 3A4 inhibitors.  Patients should be monitored for signs and symptoms of hepatotoxicity (i.e., ALT and bilirubin elevations).', 'Metabolism', 'Caution is advised if paritaprevir is prescribed in combination with potent CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297754/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Dolutegravir, More', 'Glecaprevir, Cabotegravir, Amprenavir, Zanamivir, Valaciclovir, Lenacapavir, Velpatasvir, Rilpivirine, Oseltamivir, Brincidofovir, Remdesivir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251388, 'Anisindione', 'Paritaprevir', 'Moderate', 'Liver function changes due to treatment with direct-acting HCV antiviral agents may affect the therapeutic efficacy of vitamin K antagonists.  The mechanism may involve potential pharmacokinetic changes for some vitamin K antagonists due to altered metabolism, or patients may exhibit alterations in hepatic synthesis of vitamin K-dependent coagulation factors and clearance of activated factors that could impact response to vitamin K antagonists.', 'DDInter', 'The INR should be monitored more closely following initiation or discontinuation of a direct-acting HCV antiviral agent, and the dosage of vitamin K antagonist adjusted if necessary.', 'Others', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297756/', '', 'Lamivudine, Glecaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Rilpivirine, Dolutegravir, Oseltamivir, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251389, 'Anisindione', 'Dasabuvir', 'Moderate', 'Liver function changes due to treatment with direct-acting HCV antiviral agents may affect the therapeutic efficacy of vitamin K antagonists.  The mechanism may involve potential pharmacokinetic changes for some vitamin K antagonists due to altered metabolism, or patients may exhibit alterations in hepatic synthesis of vitamin K-dependent coagulation factors and clearance of activated factors that could impact response to vitamin K antagonists.', 'DDInter', 'The INR should be monitored more closely following initiation or discontinuation of a direct-acting HCV antiviral agent, and the dosage of vitamin K antagonist adjusted if necessary.', 'Others', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297757/', '', 'Lamivudine, Glecaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Rilpivirine, Dolutegravir, Oseltamivir, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251390, 'Dasabuvir', 'Apalutamide', 'Major', 'Coadministration with potent inducers of CYP450 isoenzymes may significantly decrease the plasma concentrations of ombitasvir, paritaprevir, ritonavir, and dasabuvir.', 'DDInter', 'Concomitant use of ombitasvir/paritaprevir/ritonavir plus dasabuvir with potent CYP450 inducers such as carbamazepine, phenobarbital, phenytoin, rifampin, and St. John''s wort is considered contraindicated.', 'Metabolism', 'Concomitant use of ombitasvir/paritaprevir/ritonavir plus dasabuvir with potent CYP450 inducers such as carbamazepine, phenobarbital, phenytoin, rifampin, and St.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297759/', '', 'Tamoxifen, Anastrozole, Letrozole, Toremifene, Fulvestrant, Abarelix, Flutamide, Relugolix, Bicalutamide, Degarelix, Nilutamide, More', 'Lamivudine, Cabotegravir, Zanamivir, Valaciclovir, Telaprevir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, Elbasvir, Famciclovir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251391, 'Paritaprevir', 'Apalutamide', 'Moderate', 'Coadministration with apalutamide may decrease the plasma concentrations of drugs that are substrates of the metabolic enzymes CYP450 3A4, CYP450 2C19, CYP450 2C9, and uridine diphosphate glucuronosyltransferase (UGT), as well as substrates of the membrane transporters organic anion transporting polypeptide (OATP) 1B1, P-glycoprotein (P-gp), and breast cancer resistance protein (BCRP).', 'DDInter', 'Caution is advised when apalutamide is used concomitantly with drugs that are substrates of CYP450 3A4, CYP450 2C19, CYP450 2C9, UGT, OATP1B1, P-gp and/or BCRP, particularly sensitive substrates or those with a narrow therapeutic range.  Substitution for these medications is recommended when possible, or monitor for potential loss of therapeutic efficacy if coadministration is required.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration of a CYP450 inducer like apalutamide and for any dosage adjustments that may be required.', 'Metabolism', 'Caution is advised when apalutamide is used concomitantly with drugs that are substrates of CYP450 3A4, CYP450 2C19, CYP450 2C9, UGT, OATP1B1, P-gp and/or BCRP, particularly sensitive substrates or those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297760/', '', 'Tamoxifen, Anastrozole, Letrozole, Toremifene, Fulvestrant, Abarelix, Flutamide, Relugolix, Bicalutamide, Degarelix, Nilutamide, More', 'Lamivudine, Cabotegravir, Zanamivir, Valaciclovir, Telaprevir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, Elbasvir, Famciclovir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251392, 'Paritaprevir', 'Atazanavir', 'Major', 'Coadministration of atazanavir plus ritonavir in combination with ombitasvir/paritaprevir/ritonavir plus dasabuvir may significantly increase the plasma concentrations of paritaprevir.  The mechanism may involve inhibition of both CYP450 3A4-mediated metabolism and P-glycoprotein-mediated transport by atazanavir and ritonavir.', 'DDInter', 'When coadministered with ombitasvir/paritaprevir/ritonavir plus dasabuvir, atazanavir 300 mg should be given in the morning without ritonavir.  The ritonavir component of the HIV antiretroviral regimen should be restarted after completion of treatment with ombitasvir/paritaprevir/ritonavir plus dasabuvir.', 'Metabolism', 'When coadministered with ombitasvir/paritaprevir/ritonavir plus dasabuvir, atazanavir 300 mg should be given in the morning without ritonavir.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297764/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Dolutegravir, More', 'Cabotegravir, Amprenavir, Zanamivir, Velpatasvir, Rilpivirine, Oseltamivir, Cobicistat, Remdesivir, Famciclovir, Darunavir, Maribavir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251393, 'Paritaprevir', 'Atorvastatin', 'Major', 'Theoretically, coadministration with ombitasvir/paritaprevir/ritonavir with or without dasabuvir may significantly increase the plasma concentrations of certain HMG-CoA reductase inhibitors.  The proposed mechanism may involve inhibition of the hepatic uptake transporter OATP1B1 by paritaprevir and/or inhibition of CYP450 3A4 by ritonavir.', 'DDInter', 'Concomitant use of atorvastatin and ombitasvir/paritaprevir/ritonavir with or without dasabuvir should be avoided.  All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.', 'Metabolism', 'Concomitant use of atorvastatin and ombitasvir/paritaprevir/ritonavir with or without dasabuvir should be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297766/', '', 'Amlodipine, Ramipril, Simvastatin, Lovastatin, Rosuvastatin, Lisinopril, Perindopril, Niacin, Acetylsalicylic acid, Ezetimibe, Fenofibrate, More', 'Tenofovir alafenamide, Cabotegravir, Maraviroc, Zanamivir, Rilpivirine, Dolutegravir, Brincidofovir, Elbasvir, Doravirine, Bictegravir, Pibrentasvir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251394, 'Bempedoic acid', 'Paritaprevir', 'Moderate', 'Coadministration with bempedoic acid may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of the uptake transporters organic anion transporting polypeptide (OATP) 1B1 and 1B3.  The proposed mechanism, based on in vitro data, is decreased clearance due to bempedoic acid-mediated inhibition of OATP1B1 and 1B3.', 'DDInter', 'Caution is advised if bempedoic acid is used concomitantly with drugs that are substrates of OATP1B1 or 1B3, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever bempedoic acid is added to or withdrawn from therapy with these drugs.  Patients should be monitored for the development of adverse effects.', 'Absorption, Excretion', 'Caution is advised if bempedoic acid is used concomitantly with drugs that are substrates of OATP1B1 or 1B3, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297768/', '', 'Cholestyramine, Rosuvastatin, Fenofibrate, Mipomersen, Evinacumab, Dextrothyroxine, Simvastatin, Probucol, Cerivastatin, Lomitapide, Ezetimibe, More', 'Lamivudine, Tenofovir alafenamide, Maraviroc, Amprenavir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, Rilpivirine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251395, 'Berotralstat', 'Paritaprevir', 'Major', 'Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may significantly increase the plasma concentrations of berotralstat.  Berotralstat is a substrate of both P-gp and BCRP.', 'DDInter', 'The dosage of berotralstat should be reduced to 110 mg once daily in patients requiring chronic coadministration with P-gp and/or BCRP inhibitors.  Patients should be advised to contact their physician if they experience undue adverse effects of berotralstat such as abdominal pain, vomiting, or diarrhea.  Patients should seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.', 'Metabolism', 'The dosage of berotralstat should be reduced to 110 mg once daily in patients requiring chronic coadministration with P-gp and/or BCRP inhibitors.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297769/', '', 'Hemin, Voxelotor, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant', 'Lamivudine, Cabotegravir, Simeprevir, Zanamivir, Valaciclovir, Telaprevir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251396, 'Dasabuvir', 'Berotralstat', 'Major', 'Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may significantly increase the plasma concentrations of berotralstat.  Berotralstat is a substrate of both P-gp and BCRP.', 'DDInter', 'The dosage of berotralstat should be reduced to 110 mg once daily in patients requiring chronic coadministration with P-gp and/or BCRP inhibitors.  Patients should be advised to contact their physician if they experience undue adverse effects of berotralstat such as abdominal pain, vomiting, or diarrhea.  Patients should seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.', 'Metabolism', 'The dosage of berotralstat should be reduced to 110 mg once daily in patients requiring chronic coadministration with P-gp and/or BCRP inhibitors.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297770/', '', 'Hemin, Voxelotor, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant', 'Lamivudine, Cabotegravir, Simeprevir, Zanamivir, Valaciclovir, Telaprevir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251397, 'Dasabuvir', 'Betrixaban', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of betrixaban, which is a substrate of the efflux transporter.', 'DDInter', 'Caution is advised when betrixaban is used with P-gp inhibitors.  Closer monitoring of the pharmacologic effects of betrixaban may be appropriate whenever a P-gp inhibitor is added to or withdrawn from therapy.  Patients should be routinely evaluated for signs and symptoms suggesting blood loss such as a drop in hemoglobin and/or hematocrit, hypotension, or fetal distress (in pregnant women).  Concomitant use of betrixaban with P-gp inhibitors should be avoided in patients with severe renal impairment (CrCl<30 mL/min).', 'Excretion', 'Caution is advised when betrixaban is used with P-gp inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297771/', '', 'Ticagrelor, Apixaban, Cilostazol, Iloprost, Rivaroxaban, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Caplacizumab, More', 'Lamivudine, Paritaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Valaciclovir, Zanamivir, Rilpivirine, Etravirine, Dolutegravir, Oseltamivir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251398, 'Binimetinib', 'Paritaprevir', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp), uridine diphosphate glucuronosyltransferase (UGT) 1A1 or 2B7, and/or breast cancer resistance protein (BCRP) may increase the plasma levels and risk of adverse effects of binimetinib.  The proposed mechanism involves the reduced metabolic clearance of binimetinib through inhibition of P-gp, UGT 1A1, UGT 2B7, and/or BCRP.', 'DDInter', 'Until further information is available, caution is recommended if binimetinib must be used concomitantly with P-gp, UGT 1A1, UGT 2B7, and/or BCRP inhibitors.  Binimetinib should be monitored more closely whenever a P-gp, UGT 1A1, UGT 2B7, and/or BCRP inhibitor is added to or withdrawn from therapy, and the binimetinib dosage adjusted as necessary.', 'Metabolism', 'Until further information is available, caution is recommended if binimetinib must be used concomitantly with P-gp, UGT 1A1, UGT 2B7, and/or BCRP inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297775/', '', 'Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Fedratinib, Avapritinib, Bosutinib, Vemurafenib, Lapatinib, Selumetinib, Ribociclib, More', 'Lamivudine, Tenofovir alafenamide, Maraviroc, Cabotegravir, Zanamivir, Valaciclovir, Lenacapavir, Rilpivirine, Etravirine, Dolutegravir, Oseltamivir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251399, 'Dasabuvir', 'Binimetinib', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp), uridine diphosphate glucuronosyltransferase (UGT) 1A1 or 2B7, and/or breast cancer resistance protein (BCRP) may increase the plasma levels and risk of adverse effects of binimetinib.  The proposed mechanism involves the reduced metabolic clearance of binimetinib through inhibition of P-gp, UGT 1A1, UGT 2B7, and/or BCRP.', 'DDInter', 'Until further information is available, caution is recommended if binimetinib must be used concomitantly with P-gp, UGT 1A1, UGT 2B7, and/or BCRP inhibitors.  Binimetinib should be monitored more closely whenever a P-gp, UGT 1A1, UGT 2B7, and/or BCRP inhibitor is added to or withdrawn from therapy, and the binimetinib dosage adjusted as necessary.', 'Metabolism', 'Until further information is available, caution is recommended if binimetinib must be used concomitantly with P-gp, UGT 1A1, UGT 2B7, and/or BCRP inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297776/', '', 'Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, Selumetinib, Vandetanib, Ibrutinib, More', 'Lamivudine, Tenofovir alafenamide, Maraviroc, Cabotegravir, Zanamivir, Valaciclovir, Lenacapavir, Rilpivirine, Etravirine, Dolutegravir, Oseltamivir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (251400, 'Boceprevir', 'Paritaprevir', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of paritaprevir, which is primarily metabolized by the isoenzyme.', 'DDInter', 'Caution is advised if paritaprevir is prescribed in combination with potent CYP450 3A4 inhibitors.  Patients should be monitored for signs and symptoms of hepatotoxicity (i.e., ALT and bilirubin elevations).', 'Metabolism', 'Caution is advised if paritaprevir is prescribed in combination with potent CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/297777/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Dolutegravir, More', 'Lamivudine, Glecaprevir, Cabotegravir, Zanamivir, Valaciclovir, Lenacapavir, Telaprevir, Velpatasvir, Oseltamivir, Cobicistat, Acyclovir, More', 1767369485);
